Currently PARP inhibitors have been approved apart for ovarian cancer also for breast and pancreatic cancer patients harboring germline BRCA1/2 alterations as well as in prostate cancer patients with BRCA1/2 and other HR gene alterations, both germline and somatic. The gene discussed is BRCA1; the disease is prostate carcinoma.